The Promise and Challenge of Big Data for Pharma

The Promise and Challenge of Big Data for Pharma

The Promise and Challenge of Big Data for Pharma

The emergence of Big Data, as well as advancements in data science approaches and technology, is providing pharmaceutical companies with an opportunity to gain novel insights that can enhance and accelerate drug development. It will increasingly help government health agencies, payers, and providers to make decisions about such issues as drug discovery, patient access, and marketing. From our unique vantage points at Genentech, a leading biotechnology company with a major data science practice, and The Data Incubator, a data-science education company that places and trains data scientists, we have seen how the pharmaceuticals industry has leveraged Big Data for some potentially revolutionary advances and the challenges it has faced along the way.

For the industry, the biggest challenge by far has been talent: upgrading skill sets from those sufficient to analyze relatively small amounts of clinical trial data to those required to gain insights from the vast amount of real-world data, including unstructured data such as physicians’ notes, scans and images, and pathology reports. The pharmaceuticals industry has seen an explosion in the amount of available data beyond that collected from traditional, tightly controlled clinical trial environments. To be sure, anonymized insurance-claims data and electronic health record (EHR) data has been accessed and analyzed for many years. But in the past, EHR data was often limited to a single research institution or provider network, and obtaining the data needed to help answer a specific research question usually involved a tedious and inefficient process. While much still needs to be done to create standardized methods for sharing and making sense of anonymized EHR and genomic data across providers, it is now possible to link different data sources, which allows complex research questions to be addressed.

Read Also:
Rome Wasn’t Built in a Day, Why Should Your Analytics?

For example, the analysis of comprehensive EHR patient data collected in real time during doctor or hospital visits provides an opportunity to better understand diseases, treatment patterns, and clinical outcomes in an uncontrolled, real-world setting. These valuable insights complement those gained from clinical trials and can provide an opportunity to assess a wider spectrum of patients that are traditionally excluded from clinical trials (e.g., elderly, frail, or immobile patients, as well as people with rare indications and diseases not yet studied in clinical trials). It also allows companies to assess real-world challenges that cannot be observed in a clinical trial, such as drug compliance and the utilization of health care resources.

While these advances are generating great opportunities, they also pose resourcing and capability development challenges. One of the biggest is how to make the transition from legacy technology and analytical competence to more-powerful and sophisticated analytical tools and analysis methodologies.

 



Read Also:
Internet of Things: Connecting the Digital to the Physical World

Data Science Congress 2017

5
Jun
2017
Data Science Congress 2017

20% off with code 7wdata_DSC2017

Read Also:
Are We Losing Our Jobs To Big Data?

AI Paris

6
Jun
2017
AI Paris

20% off with code AIP17-7WDATA-20

Read Also:
10 Interesting Business Use Cases of Internet of Things (IoT)

Chief Data Officer Summit San Francisco

7
Jun
2017
Chief Data Officer Summit San Francisco

$200 off with code DATA200

Read Also:
4 Data Trends That Will Dominate 2017

Customer Analytics Innovation Summit Chicago

7
Jun
2017
Customer Analytics Innovation Summit Chicago

$200 off with code DATA200

Read Also:
5 ethics principles big data analysts must follow

HR & Workforce Analytics Innovation Summit 2017 London

12
Jun
2017
HR & Workforce Analytics Innovation Summit 2017 London

$200 off with code DATA200

Read Also:
Data Quality for Analytics: Clean Input Drives Better Decisions

Leave a Reply

Your email address will not be published. Required fields are marked *